Header Logo

Connection

MOHIT KHERA to Hypogonadism

Back to Details
This is a "connection" page, showing publications MOHIT KHERA has written about Hypogonadism.
MOHIT KHERA
Connection Strength
14.571
Hypogonadism
  1. Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sex Med Rev. 2025 Oct 04; 13(4):548-573.
    View in: PubMed
    Score: 0.713
  2. Trends in blood-based metabolic and cardiovascular risk profiles in men during treatment for testosterone deficiency: a longitudinal, retrospective cohort study. J Sex Med. 2025 Sep 04; 22(9):1564-1571.
    View in: PubMed
    Score: 0.709
  3. Testosterone deficiency and treatments: common misconceptions and practical guidance for patient care. Sex Med Rev. 2025 Jul 03; 13(3):373-380.
    View in: PubMed
    Score: 0.701
  4. Testosterone replacement therapy and cardiovascular disease. Int J Impot Res. 2022 Nov; 34(7):685-690.
    View in: PubMed
    Score: 0.550
  5. Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk. J Sex Med. 2021 01; 18(1):83-98.
    View in: PubMed
    Score: 0.511
  6. Controversies in Testosterone Therapy. Sex Med Rev. 2021 01; 9(1):149-159.
    View in: PubMed
    Score: 0.511
  7. Hypogonadism management and cardiovascular health. Postgrad Med. 2020 Dec; 132(sup4):35-41.
    View in: PubMed
    Score: 0.506
  8. Testosterone Replacement Therapy Versus Clomiphene Citrate in the Young Hypogonadal Male. Eur Urol Focus. 2018 04; 4(3):321-323.
    View in: PubMed
    Score: 0.435
  9. The Role of Testosterone Therapy in the Setting of Prostate Cancer. Curr Urol Rep. 2018 Jun 30; 19(8):67.
    View in: PubMed
    Score: 0.431
  10. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism. J Sex Med. 2018 02; 15(2):148-158.
    View in: PubMed
    Score: 0.419
  11. Hypogonadism: Therapeutic Risks, Benefits, and Outcomes. Med Clin North Am. 2018 Mar; 102(2):361-372.
    View in: PubMed
    Score: 0.415
  12. Alternatives to Testosterone Therapy: A Review. Sex Med Rev. 2018 01; 6(1):106-113.
    View in: PubMed
    Score: 0.414
  13. Testosterone therapy improves erectile function and libido in hypogonadal men. Curr Opin Urol. 2017 Nov; 27(6):511-515.
    View in: PubMed
    Score: 0.412
  14. Clinical Characteristics, Health Care Utilization and Costs Among Men with Primary or Secondary Hypogonadism in a US Commercially Insured Population. J Sex Med. 2017 01; 14(1):88-97.
    View in: PubMed
    Score: 0.387
  15. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM?2015). J Sex Med. 2016 12; 13(12):1787-1804.
    View in: PubMed
    Score: 0.386
  16. Adult-Onset Hypogonadism. Mayo Clin Proc. 2016 07; 91(7):908-26.
    View in: PubMed
    Score: 0.375
  17. Testosterone Therapies. Urol Clin North Am. 2016 May; 43(2):185-93.
    View in: PubMed
    Score: 0.368
  18. Alternative treatment modalities for the hypogonadal patient. Curr Urol Rep. 2014 Jul; 15(7):417.
    View in: PubMed
    Score: 0.327
  19. Controversies in the treatment of male hypogonadism. Urology. 2014 Apr; 83(4):957.
    View in: PubMed
    Score: 0.321
  20. 12-month observation of testosterone replacement effectiveness in a general population of men. Postgrad Med. 2013 Mar; 125(2):8-18.
    View in: PubMed
    Score: 0.298
  21. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013 Aug; 190(2):639-44.
    View in: PubMed
    Score: 0.297
  22. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013 Jan; 25(1):24-8.
    View in: PubMed
    Score: 0.288
  23. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. J Androl. 2012 Sep-Oct; 33(5):927-37.
    View in: PubMed
    Score: 0.278
  24. Subcutaneous implantable testosterone pellets overcome noncompliance in adolescents with Klinefelter syndrome. J Androl. 2012 Jul-Aug; 33(4):570-3.
    View in: PubMed
    Score: 0.270
  25. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011 Nov; 8(11):3204-13.
    View in: PubMed
    Score: 0.267
  26. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011 Sep; 186(3):1005-11.
    View in: PubMed
    Score: 0.266
  27. The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism. Int J Impot Res. 2010 Jan-Feb; 22(1):20-4.
    View in: PubMed
    Score: 0.233
  28. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009 Apr; 6(4):1165-1170.
    View in: PubMed
    Score: 0.224
  29. Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med. 2009 Mar; 6 Suppl 3:234-8.
    View in: PubMed
    Score: 0.224
  30. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am. 2007 Nov; 34(4):549-53, vi.
    View in: PubMed
    Score: 0.206
  31. Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. Andrology. 2025 May; 13(4):882-893.
    View in: PubMed
    Score: 0.166
  32. Changes in post-transplant serum testosterone levels in men undergoing lung transplantation: a pilot study using the TriNetX Research Network. Int J Impot Res. 2025 Aug; 37(8):595-600.
    View in: PubMed
    Score: 0.163
  33. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):569-580.
    View in: PubMed
    Score: 0.158
  34. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 12 01; 6(12):e2348692.
    View in: PubMed
    Score: 0.157
  35. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023 07 13; 389(2):107-117.
    View in: PubMed
    Score: 0.152
  36. Oral testosterone therapy: past, present, and future. Sex Med Rev. 2023 04 03; 11(2):124-138.
    View in: PubMed
    Score: 0.150
  37. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism. Andrology. 2022 05; 10(4):669-676.
    View in: PubMed
    Score: 0.138
  38. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022 03; 245:41-50.
    View in: PubMed
    Score: 0.137
  39. Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100?mg IM weekly or 200?mg IM biweekly. Int J Impot Res. 2022 Sep; 34(6):558-563.
    View in: PubMed
    Score: 0.133
  40. Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men. J Cardiovasc Pharmacol Ther. 2021 11; 26(6):630-637.
    View in: PubMed
    Score: 0.133
  41. Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature. Sex Med Rev. 2021 07; 9(3):393-405.
    View in: PubMed
    Score: 0.129
  42. Is treatment of hypogonadism safe for men after a solid organ transplant? Results from a retrospective controlled cohort study. Int J Impot Res. 2022 Jan; 34(1):50-54.
    View in: PubMed
    Score: 0.126
  43. Controversies with testosterone therapy. Can J Urol. 2020 08; 27(S3):20-23.
    View in: PubMed
    Score: 0.125
  44. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers. 2019 May 30; 5(1):38.
    View in: PubMed
    Score: 0.115
  45. Practice Patterns in the Diagnosis and Management of Hypogonadism: A Survey of Sexual Medicine Society of North America Members. Urology. 2017 Aug; 106:87-95.
    View in: PubMed
    Score: 0.099
  46. Diagnosing secondary hypogonadism: important consequences for fertility and reversibility. BJU Int. 2016 Apr; 117(4):552-4.
    View in: PubMed
    Score: 0.090
  47. The nanochannel delivery system for constant testosterone replacement therapy. J Sex Med. 2015 Jun; 12(6):1375-80.
    View in: PubMed
    Score: 0.087
  48. The safety of testosterone supplementation therapy in prostate cancer. Nat Rev Urol. 2014 Sep; 11(9):526-30.
    View in: PubMed
    Score: 0.082
  49. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry. Postgrad Med. 2013 Mar; 125(2):19-29.
    View in: PubMed
    Score: 0.074
  50. The treatment of hypogonadism in?men of reproductive age. Fertil Steril. 2013 Mar 01; 99(3):718-24.
    View in: PubMed
    Score: 0.073
  51. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Clin Interv Aging. 2012; 7:321-30.
    View in: PubMed
    Score: 0.072
  52. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS). Pain Med. 2012 May; 13(5):688-98.
    View in: PubMed
    Score: 0.070
  53. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(?)) insertion. J Sex Med. 2012 Feb; 9(2):594-601.
    View in: PubMed
    Score: 0.069
  54. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male. 2012 Mar; 15(1):14-21.
    View in: PubMed
    Score: 0.068
  55. Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med. 2011 May; 123(3):17-27.
    View in: PubMed
    Score: 0.066
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.